203 related articles for article (PubMed ID: 34290287)
1. Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis.
Wang A; Karunasinghe N; Plank LD; Zhu S; Osborne S; Brown C; Bishop K; Schwass T; Tijono S; Holmes M; Masters J; Huang R; Keven C; Ferguson LR; Lawrenson R
Sci Rep; 2021 Jul; 11(1):14905. PubMed ID: 34290287
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids.
García-Fontana B; Morales-Santana S; Varsavsky M; García-Martín A; García-Salcedo JA; Reyes-García R; Muñoz-Torres M
Osteoporos Int; 2014 Feb; 25(2):645-51. PubMed ID: 23903956
[TBL] [Abstract][Full Text] [Related]
3. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
[TBL] [Abstract][Full Text] [Related]
5. The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.
Anagnostis P; Vakalopoulou S; Christoulas D; Paschou SA; Papatheodorou A; Garipidou V; Kokkoris P; Terpos E
Haemophilia; 2018 Mar; 24(2):316-322. PubMed ID: 29194852
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
[TBL] [Abstract][Full Text] [Related]
8. Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study.
Wang A; Karunasinghe N; Plank L; Zhu S; Osborne S; Bishop K; Brown C; Schwass T; Masters J; Holmes M; Huang R; Keven C; Ferguson L; Lawrenson R
Clin Med Insights Oncol; 2017; 11():1179554917733449. PubMed ID: 29051709
[TBL] [Abstract][Full Text] [Related]
9. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
Kiratli BJ; Srinivas S; Perkash I; Terris MK
Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
[TBL] [Abstract][Full Text] [Related]
10. Serum osteoprotegerin and sex steroid levels in patients with prostate cancer.
Varsavsky M; Reyes-Garcia R; Avilés Perez MD; Gonzalez Ramírez AR; Mijan JL; Muñoz-Torres M
J Androl; 2012; 33(4):594-600. PubMed ID: 21903971
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy.
Wang W; Yuasa T; Tsuchiya N; Maita S; Kumazawa T; Inoue T; Saito M; Ma Z; Obara T; Tsuruta H; Satoh S; Habuchi T
Endocr Relat Cancer; 2008 Dec; 15(4):943-52. PubMed ID: 18667685
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy.
Dalla Via J; Daly RM; Owen PJ; Mundell NL; Rantalainen T; Fraser SF
Bone; 2019 Oct; 127():367-375. PubMed ID: 31189088
[TBL] [Abstract][Full Text] [Related]
14. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.
Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF
J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949
[TBL] [Abstract][Full Text] [Related]
15. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
16. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
[TBL] [Abstract][Full Text] [Related]
18. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children.
Guven S; Gokce I; Cicek N; Yaman A; Vatansever P; Alpay H
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1383-1390. PubMed ID: 33068383
[TBL] [Abstract][Full Text] [Related]
20. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]